Info@ThinkPinkRocks.com

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.

Link:
IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Share

Leave a Reply

Solve : *
29 + 29 =